Analysts at Jefferies see blockbuster potential in zorevunersen in Dravet syndrome, with sales potentially reaching $1 ...

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the ...

Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in ...

In late November and early December 2025, Biogen and its partners Eisai, Stoke Therapeutics and Dayra Therapeutics reported new clinical data and collaborations spanning Alzheimer’s disease, Dravet ...

Encoded Therapeutics has linked its Dravet syndrome gene therapy ETX101 to a 78% reduction in seizures, keeping the biotech ...

Discover Stoke Therapeutics' promising RNA therapies and market outlook. Learn the risks and commercial potential before investing in STOK shares.

Stoke Therapeutics (STOK) and Biogen (BIIB) announced data presentations on zorevunersen, an investigational antisense oligonucleotide, as a ...

The Scientist's Top Innovations competition spotlights the technologies transforming research and healthcare. Each year's honorees?from disruptive new instruments to creative updates on proven methods ...

Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced on 5th that it participated in the 111th ...

Biogen (BIIB) and Stoke Therapeutics (STOK) announced data presentations that further support the potential of zorevunersen, an investigational ...

Neuropathic Pain Market Size To Surpass $15.37 Billion By 2033, Driven By Surging Prevalence Of Diabetes, Cancer Cases & Advances In Non-Opioid Therapies SNS Insider. SNS Insider Highlights U.S.